Silence Therapeutics (SLN) Current Deferred Revenue (2019 - 2025)
Historic Current Deferred Revenue for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $301000.0.
- Silence Therapeutics' Current Deferred Revenue rose 10039.97% to $301000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $301000.0, marking a year-over-year increase of 10039.97%. This contributed to the annual value of $306000.0 for FY2024, which is 9534.32% down from last year.
- Per Silence Therapeutics' latest filing, its Current Deferred Revenue stood at $301000.0 for Q3 2025, which was up 10039.97% from $457000.0 recorded in Q2 2025.
- Silence Therapeutics' Current Deferred Revenue's 5-year high stood at $10.4 million during Q4 2022, with a 5-year trough of -$90.0 million in Q1 2022.
- In the last 5 years, Silence Therapeutics' Current Deferred Revenue had a median value of -$73.3 million in 2023 and averaged -$51.0 million.
- As far as peak fluctuations go, Silence Therapeutics' Current Deferred Revenue plummeted by 80325.49% in 2023, and later soared by 10062.22% in 2025.
- Silence Therapeutics' Current Deferred Revenue (Quarter) stood at $5.7 million in 2021, then soared by 81.6% to $10.4 million in 2022, then plummeted by 803.25% to -$73.1 million in 2023, then skyrocketed by 100.42% to $306000.0 in 2024, then fell by 1.63% to $301000.0 in 2025.
- Its last three reported values are $301000.0 in Q3 2025, $457000.0 for Q2 2025, and $392000.0 during Q1 2025.